Figure 33

See text for description.

Area graph showing the distribution of primary antimicrobial drug used to treat gonorrhea among GISP participants from 1988 to 2018. The proportion of GISP participants treated for gonorrhea with ceftriaxone 250 mg increased from 84.0% in 2011 to 98.1% in 2017 but decreased slightly to 96.5% in 2018. Participants treated with gentamicin 240 mg increased from 0.2% in 2015 to 1.4% in 2018 and participants treated with cefixime 400 mg decreased from 0.3% in 2015 to 0.1% in 2018.